Drugs / CLE-100
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06340958 | Mar 2024 → Jun 2025 | — | Clexio Biosciences Ltd. | Completed | Missed primary |
| Phase 2 | NCT04103892 | Sep 2019 → Sep 2022 | — | Clexio Biosciences Ltd. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLE-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04103892 ↗ |
| Known as | esketamine | “CLE-100 (oral esketamine)” NCT04103892 ↗1“CLE-100 (oral esketamine)” NCT06340958 ↗ |
| Route | Oral | “1 oral tablet of CLE-100 once daily” NCT04103892 ↗ |